Sputnik Light: SEC recommends permission for phase 3 trial as booster dose



An expert panel of India’s central drug authority has recommended the permission for conducting phase-3 clinical trial of single-dose COVID-19 vaccine ‘Sputnik Light’ as a booster dose, official sources said on Saturday.


The recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.





The DCGI had on February 4 granted emergency use permission to Sputnik Light vaccine in India, subject to certain regulatory provisions.


Hyderabad-based Dr. Reddy’s Laboratories had presented its proposal to DCGI for conducting the phase-3 trial of Sputnik Light vaccine as booster dose.


Sputnik Light is the same as component-1 of Sputnik V.


“The Subject Expert Committee (SEC) on COVID-19 of the CDSCO, which reviewed the application on Friday after detailed deliberation, recommended granting permission for the phase-3 clinical trial with condition to initiate the trial with Sputnik Light vaccine for which the firm is holding emergency use authorisation permission in the country subject to certain regulatory provisions,” an official source said.


Sputnik Light vaccine is approved in 29 countries, including Argentina and Russia.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Education News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.